Amneal Pharmaceuticals announced the FDA has accepted for review the Biologics License Application (BLA) for bevacizumab biosimilar for the treatment of metastatic colorectal cancer, in combination with intravenous… read more.
Pancreatic cancer is an aggressive disease in which malignant cells form in the tissues of the pancreas, a long and flat gland located behind the stomach that helps… read more.
Article written by Bruce Sylvester. In locally advanced cervical cancer, use of adjuvant chemotherapy after standard chemoradiation does not improve mortality outcomes. Researchers reported this finding on June… read more.
Article written by Bruce Sylvester. Researchers report that both single and dual immunotherapy improve overall survival among patients with advanced esophageal squamous cell carcinoma, particularly those positive for… read more.
Researchers at the Francis Crick Institute have identified a protein that helps tumours evade the immune system and, in certain types of cancers, is linked to a poorer… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase III MAIA (NCT02252172) study showing the addition of Darzalex (daratumumab) to lenalidomide… read more.
Bristol Myers Squibb announced positive topline results from TRANSFORM, a global, randomized, multicenter Phase III study evaluating Breyanzi (lisocabtagene maraleucel) as a second-line treatment in adults with relapsed… read more.
Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June… read more.
Genentech, a member of the Roche Group announced the latest data from three pivotal Phase III studies of Venclexta (venetoclax) – CLL14, MURANO and VIALE-A – to be… read more.
Article written by Bruce Sylvester. When treated with adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy, patients with high-risk, HER2-negative early breast cancer and… read more.
Researchers at UVA Cancer Center have unveiled important new insights into how hormones known as androgens act on our cells — and the discovery could boost efforts to… read more.
Seagen Inc. announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
